Persistent complete molecular remission after ponatinib discontinuation in a patient with chronic myelogenous leukemia and T315I-mutation

被引：0
|
作者：
Wang, S. -Y. [1 ]
Jaekel, N. [1 ]
Schulze, S. [1 ]
Kovacs, I. [1 ]
Schwabe, S. [1 ]
Franke, G. -N. [1 ]
Niederwieser, D. [1 ]
机构：
[1] Uniklin Leipzig, Hamatol & Internist Onkol, Leipzig, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P562
引用
收藏
页码：155 / +
页数：2
相关论文
共 50 条
  • [1] Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib
    Nickel, Robert Sheppard
    Daves, Marla
    Keller, Frank
    PEDIATRIC BLOOD & CANCER, 2015, 62 (11) : 2050 - 2051
  • [2] Complete molecular remission in chronic myelogenous leukemia after imatinib therapy
    Barbany, G
    Höglund, M
    Simonsson, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07): : 539 - 540
  • [3] Rapid Quantitative Detection of the T315I Mutation in Patients With Chronic Myelogenous Leukemia
    Yin, Lihui
    Dittman, David
    Chenn, Anjen
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (01) : 34 - 39
  • [4] Sustained Complete Molecular Remission after Imatinib Discontinuation in Children with Chronic Myeloid Leukemia
    Moser, Olga
    Krumbholz, Manuela
    Thiede, Christian
    Tauer, Josephine T.
    Janz, Indra
    Lauten, Melchior
    Dilloo, Dagmar
    Metzler, Markus
    Suttorp, Meinolf
    PEDIATRIC BLOOD & CANCER, 2014, 61 (11) : 2080 - 2082
  • [5] Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission:: An update follow up.
    Mahon, Francois-Xavier
    Huguet, Francoise
    Etienne, Gabriel
    Réa, Delphine
    Cayuela, Jean-Michel
    Marit, Gerald
    Gardembas, Martine
    Reiffers, Josy
    Philippe, Rousselot
    BLOOD, 2006, 108 (11) : 611A - 611A
  • [6] Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    Rousselot, Philippe
    Huguet, Francoise
    Rea, Delphine
    Legros, Laurence
    Cayuela, Jean Michel
    Maarek, Odile
    Blanchet, Odile
    Marit, Gerald
    Gluckman, Eliane
    Reiffers, Josy
    Gardembas, Martine
    Mahon, Francois-Xavier
    BLOOD, 2007, 109 (01) : 58 - 60
  • [7] Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation
    Zhou, Jinyi
    Qu, Qi
    Chen, Suning
    Xu, Yang
    Shen, Hongjie
    Cen, Jiannong
    Wu, Depei
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3207 - 3209
  • [8] Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation
    Ferri, Cristian A.
    Bianchini, Michele
    Bengio, Raquel M.
    Moiraghi, Elena B.
    Gonzalez, Mariana S.
    Noriega, Maria F.
    Larripa, Irene B.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 270 - 272
  • [9] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Ishii
    Daigo Akahane
    Kousuke Nunoda
    Seiko Honda
    Tomoiku Takaku
    Kazuma Ohyashiki
    International Journal of Hematology, 2007, 85 : 173 - 174
  • [10] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ishii, Yuko
    Akahane, Daigo
    Nunoda, Kousuke
    Honda, Seiko
    Takaku, Tomoiku
    Ohyashiki, Kazuma
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (02) : 173 - 174
12345